How to Capture the Trillion-Yuan Aesthetic Medicine Market and Build a Complete Ecosystem Chain? VB Insight and Mingfeng Capital Provide Answers

According to data from Qichacha, the number of deregistered enterprises in China's medical aesthetics industry increased significantly from 2016 to 2019.In 2018, a total of 34,508 medical aesthetics companies were deregistered, representing a 3.8-fold increase compared to 2016.By 2019, a total of 2,600 medical aesthetic hospitals had closed down throughout the year, including many large and medium-sized institutions. Behind this trend, in addition to the impact of the pandemic, intensifying competition in the medical aesthetics industry, and increasingly rational consumers, there were alsoPractitioners in the medical aesthetics industry place excessive emphasis on “blunt” marketing tactics—such as search engine advertising and offline building advertisements—to identify potential customers, relying heavily on price wars to drive traffic conversion.The direct consequence is that the medical aesthetics industry remains heavily reliant on offline channels and traffic-driven platforms, with customer acquisition costs persistently high.

Admittedly, in the early stages of the medical aesthetics industry’s development, relevant institutions struggled to attract clients through brand recognition alone, thus focusing their competitive efforts on publicity and promotion. ButAs the industry matures and consumers enjoy a wider range of choices, competition among medical aesthetic institutions has shifted from battles over distribution channels and traffic acquisition to a contest for consumer mindshare.As the medical aesthetics industry accelerates its consolidation in the face of new challenges, new business models are rapidly emerging. In this process, identifying new growth drivers to restore and boost performance has become an urgent priority for every medical aesthetics institution.

In this context,VCBeatCombineMingfeng Capital, in2021Afternoon of April 18, co-hosted byThe 5th Future Healthcare Top 100 Conference · Medical Aesthetics Industry Innovation Forum, we will discuss new developments and trends in the medical aesthetics industry from four perspectives—regulation, technology, innovation, and “Internet Plus”—explore how to promote high-quality development in the sector, build a more comprehensive ecosystem, and drive the next wave of industrial upgrading.

We have invited to this forumMingfeng Capital、Imeik、iRay Medical、Longma Peak Ventures、Chengdu BadadaPrescription、Lancy Medical Aesthetics、Ruili Plastic Surgery、Daimai Micro-needle Hair Transplant Global Chain Hospitals、Lanshi Technology Management、Alibabarepresentatives from all parties.

Guest:Jin Xuekun | Founding Partner, Mingfeng Capital

Topic:Value Distribution of the Medical Aesthetics Industry Chain from an Investment Perspective

On December 29 last year, the Gengmei app released the “2020 White Paper on the Medical Aesthetics Industry.” The white paper showed that despite the impact of the pandemic last year, China’s pure medical aesthetics market still reached RMB 197.5 billion, accounting for 17% of the global market, and is poised to become the world’s largest medical aesthetics market. From an investment perspective, how is value distributed across the medical aesthetics industry chain?

Guest:Chen Long | Head of Investment, Imeik

Topic:Insights for Chinese Medical Aesthetics Companies from Global Leaders in the Industry

A Global Overview of Aesthetic Medicine: Charting the Optimal Path for Chinese Aesthetic Medicine Enterprises in Light of Industry Trends

Guest:Li Yong | Dean of Chengdu Badachu; Zhao Heng | General Manager of Medical Aesthetics, Langzi Shares; Fu Haishu | Chairman of the Board, Ruili Plastic Surgery

Topic:The Medical Aesthetics Body Contouring Market Is Poised for a Major Boom: How Can Medical Aesthetics Service Providers Seize the Opportunity?

For years, competition in China’s medical aesthetics industry has primarily revolved around the “face,” with facial treatments generating a market size exceeding RMB 150 billion and multiple breakout procedures targeting the face. As supply and demand dynamics shift, the “face” segment can no longer sustain its previous high growth rate.After growth slows, it is necessary to identify new growth drivers, namely, untapped market opportunities.Currently, China's body contouring market has entered a period of rapid growth, with a compound annual growth rate (CAGR) of approximately 28%. The market size is projected to reach RMB 10 billion in 2020 and surpass RMB 100 billion by 2030. This blue-ocean market for body contouring is poised to become the most powerful growth engine for China's medical aesthetics industry.

Guest:Li Xingdong | Founder of Daimai Microneedle Hair Transplant Global Chain Hospitals

Agenda:China’s “Future” Hair Transplant Market

 Hair care, hair growth, and hair transplantation have seemingly emerged overnight. In particular, the hair transplantation industry has maintained a remarkably high growth rate in recent years, leading to explosive expansion. Judging by current trends, the “head” market still holds significant potential. How to sustain this growth is the topic we aim to explore.。

Guest:Liu Hongyu | Managing Partner and Chief Operating Officer, Lanshi Technology

Agenda:AI-Powered SaaS Solutions Drive the Development of the Traditional Medical Aesthetics Industry

The beauty industry is in urgent need of business model transformation, requiring accelerated innovation and strategic repositioning. By leveraging the momentum of medical aesthetic SaaS intelligent software, this analysis examines the opportunities and challenges facing the traditional medical aesthetics sector, aiming to facilitate its upgrade and development.

Guest:Wang Yajun | General Manager, Healthcare Division of Alibaba Local Services

Topic:Construction and Practice of the Closed-Loop Ecosystem for Medical Aesthetics Live Streaming in the Digital Economy

Doctors and nursing staff move from the consultation desk to behind the screen, engaging directly with consumers online alongside live-streaming influencers. This enables consumers to consult and inquire about pricing in real time, reducing intermediary involvement and safeguarding the interests of both parties. So, how exactly should we build a closed-loop ecosystem for medical aesthetics live streaming to drive the industry’s next-level upgrade?

April 16-18, 2021，VCBeatJoint UnionPeople's Government of Wujiang District, Suzhou City、Guangdong Zhong Nanshan Medical Foundation、Suzhou Wujiang Dongfang State-owned Capital Investment and Operation Co., Ltd.InSuzhou · WujiangCo-hosted byThe 5th Future Healthcare 100 Conference. The conference will focus on the healthcare industry, with attention to individual health, public health, the healthcare industry chain, and supporting infrastructure systems. For the first time, it will explore the conference’s industrial ecosystem, connecting more possibilities in healthcare and achieving a comprehensive upgrade of the Top 100 Conference.

Confirmed Participating Companies at the 5th Future Healthcare 100 Conference:Microsoft, Intel, IBM, BOE, AliHealth, AstraZeneca, Takeda Pharmaceutical, Sanofi, GE, Roche, Terumo, Medtronic, New Horizon Health, Langzi Shares, Clarivate, Agilent, Livongo, Hims & Hers, BGI Group, JD Health, Sansure Biotech, Tigermed, Dian Diagnostics, KingMed Diagnostics, Wondfo, Winning Health Technology Group, DHC Software, Genetron Health, Imeik, BaiRen Medicaletc.

>>>> Partially Confirmed Guests

Zhang Zhiyuan| Academician of the Chinese Academy of Engineering

Chen Shiqing| Member of the U.S. National Academy of Engineering, Supercomputing Expert

Li Changming| Dean of the School of Materials Science and Engineering, Suzhou University of Science and Technology; Academician of Academia Europaea

Timothy Johns | Digital Health Officer, British Consulate-General in Shanghai

Song Yijun| Representative of the Government of Ontario, Canada; Commercial Counsellor, Canadian Embassy in China

Sun Baoqing| Chairman of the Guangdong Zhong Nanshan Medical Foundation

Nick Rodgers| Chair of the UK South East MedTech Alliance, Chair of Destiny Pharma

Wang Tianmiao| Professor at Beihang University

Wang Jingjing| Executive Director, Tsinghua University Global Health Industry Innovation Center

Jane Jin | Head of Oxford University's Technology Transfer Office, China Region

Zhi Zhang | Business Development Manager, Technology Division, UK Medical Research Council |

Chen Fangxia| Director of Business Development, Asia Technology Transfer Center, Western University, Canada

Kimon Angelides | Founder, Livongo & Vivante

Luo Zhangwei| Chief Scientist, Suzhou Smart Healthcare Innovation Center; Former Chief AI Scientist, Siemens China Research Institute, Suzhou Branch

Liu Enmei| Deputy Director, Children's Hospital of Chongqing Medical University (Liangjiang Campus)

Chen Hongxiang| Executive Vice President, Union Shenzhen Hospital of Huazhong University of Science and Technology (Nanshan Hospital)

Tao Liang| President of Wuhan Asia Heart Hospital

Zhang Nuofu| Vice President of the First Affiliated Hospital of Guangzhou Medical University

Weng Jianping| Deputy Director of the Division of Life Sciences and Medicine, University of Science and Technology of China; President of Bengbu Medical College

Lei Juan| Deputy Director of the West China Transfer Center, West China Hospital of Sichuan University

Wei Xuejie| Vice President of Xuzhou Mining Group General Hospital

Ye Xin| Deputy Director of Yilianzhong Beijing Research Institute

Wu Xia| Managing Director, CICC Capital

Zhang Man| Vice President, China Renaissance

Wang Xiaohui| Managing Partner, Shengjing Jiacheng Fund of Funds

Hu Chuanwei| Vice President, Hengqin Financial Investment Group

Li Yuhui| Founding Managing Partner, Panlin Capital

Yu Zhengkun| Founding Partner of Jifeng Capital

Zhou Yi| Partner, Shenzhen Capital Group Health Industry Fund

Tian Min| Partner, Yuanjing Capital

Tang Haofu| Chairman of Chuangrui Investment

Ren Bobing| Executive Director of Sinovation Ventures

Andrew Craig| WG Fund Partner

……

>>>> Conference Highlights

Top-Tier Guest Lineup—Led by Academicians and IEEE Fellows200+Industry Leaders Present the Cutting-Edge Medical Technologies, Industry Trends, and Business Innovations Over Three Days

Business Wisdom of Industry Leaders—10Strategic Launch by Leading Publicly Listed Companies: Insights into the Industry’s Future and Innovation Landscape

Global Perspective and Overseas Resources — FromUnited Kingdom, Israel, United States, Canada, Belgium, Germany, Denmarkand the industrial development trends and capital markets of multiple countries, linking high-quality overseas technological innovation projects

In-Depth Insights into Niche Sectors—Major Release10 copiesIndustry Research Series: Exploring Development Opportunities and Innovative Cases in Niche Sectors

Converging the Core Forces of Future Healthcare – Release6 MajorTop 100 Lists and Awards, Converged1000+Unicorns and High-Potential Innovative Enterprises Jointly Explore Pathways for Innovative Development

Emphasizing Research Translation—Invitation10+Hospital Presidents, Research and University Experts: Breaking Boundaries to Explore the Integration of Industry and Research

A Forward-Looking Capital Perspective——100+Including forward-looking investors from GP, LP, CVC, VC, PE, FA and other financial institutions to perceive the direction of capital heat in the industry

Harnessing the Momentum of the Industrial Ecosystem——10+Ecosystem Conference for Investment Institutions and Industry Giants: Promoting Integration and Fission in the Industrial Ecosystem

http://vb100.vcbeat.top/

Click the link or scan the QR code to view conference details and purchase tickets.

>>>> About Mingfeng Capital

In recent years, Wujiang has seized new opportunities presented by the latest round of industrial transformation, vigorously fostering the development of the life and health industry. The sector has begun to take shape, giving rise to a large number of backbone enterprises such as Zhonghe Biotechnology, Shengda Pharmaceutical, Haian Pharmaceutical, Jiecheng Medical, Langkai Medical, Junmeng Biotechnology, Chukai Pharmaceutical, Weikang Biotechnology, and Nearshore Protein. A number of scientific and technological achievements have entered clinical trials and industrialization stages. Looking ahead, Wujiang District will focus on pharmaceutical biotechnology, novel medical devices, and comprehensive health services, actively building an integrated full-industry-chain system encompassing “R&D innovation–pilot-scale acceleration–industrialization.”